Capricor Therapeutics (CAPR) Operating Expenses (2010 - 2026)

Capricor Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $36.8 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 47.19% year-over-year to $36.8 million in Q1 2026; TTM through Mar 2026 was $119.9 million, a 60.67% increase from a year earlier, with the FY2025 full-year figure at $108.1 million, up 66.8% from the prior year.
• Operating Expenses climbed to $36.8 million in Q1 2026 per CAPR's latest filing, from $29.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $36.8 million in Q1 2026 and bottomed at $7.3 million in Q2 2022.
• The 5-year median for Operating Expenses is $15.2 million (2024), against an average of $17.1 million.
• Across the five-year window, Operating Expenses jumped 87.03% in 2022 and rose 17.02% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $9.0 million in 2022, then surged by 48.12% to $13.4 million in 2023, then surged by 40.82% to $18.8 million in 2024, then surged by 54.86% to $29.2 million in 2025, then increased by 26.12% to $36.8 million in 2026.
• Per Business Quant, the three latest CAPR Operating Expenses figures stand at $36.8 million (Q1 2026), $29.2 million (Q4 2025), and $26.3 million (Q3 2025).